Breaking News, Collaborations & Alliances

Gilead, Goldfinch Enter Kidney Collaboration

Companies to pursue a human genetics approach to drug discovery and development in a deal worth up to $2 billion

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences and Goldfinch Bio have entered a collaboration to discover, develop and commercialize a pipeline of therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.   Under the multi-year collaboration, Gilead has exclusive options to license worldwide rights to certain products directed toward targets emerging from Goldfinch’s proprietary Kidney Genome Atlas (KGA), a comprehensive registry of patients with kidney diseases integrating genomic, transcriptomic and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters